Dr. Horwitz Discusses the Results of the ECHELON-2 Study

Video

In Partnership With:

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

In this phase III study of patients with CD30-expressing PTCL, the addition of brentuximab vedotin (Adcetris) to chemotherapy led to a clinically meaningful improvement in progression-free survival (PFS) and overall survival. The primary endpoint was PFS per blinded independent central review.

Findings showed a 29% reduction in the risk of disease progression, a 34% reduction in the risk of death, and a 3-year PFS rate of 57.1% versus 44% with CHOP. PFS benefit was generally observed across all patient subgroups, most notably in patients with ALK-positive systemic anaplastic large cell lymphoma.

Brentuximab vedotin was approved by the FDA in November 2018 for the frontline treatment of patients with CD30-expressing PTCL in combination with chemotherapy. Previously, the frontline standard of care for patients with PTCL has been CHOP or a CHOP-like regimen with curative intent.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD